BRAF and Miyoshi myopathy: investigated the efficacy of vemurafenib compared to dacarbazine, the only chemotherapeutic drug approved for metastatic MM therapy, in a phase III randomized clinical trial including 675 patients with untreated, metastatic MM carrying the BRAF V600E mutation.